2 employees
Dnovobio is a developer of a direct reprogramming technology intended to create any cell, tissue, or organ on demand.
2018
$2.7M
from 4 investors over 4 rounds
dNovo Inc raised $2.7M on January 24, 2022
Investors: Pioneer Fund, Y Combinator and Soma Capital
dNovo Inc raised undisclosed on January 1, 2018
Investors: Soma Capital